Who is sponsoring NCT05594797?

NCT05594797 is sponsored by Hrain Biotechnology Co., Ltd..

What drugs are being tested in NCT05594797?

Interventions in NCT05594797: Human BCMA Targeted T Cells Injection.

What condition does NCT05594797 study?

NCT05594797 studies Multiple Myeloma.

Is NCT05594797 still recruiting?

NCT05594797 is currently recruiting now. Last updated 9 December 2022.

Last reviewed 2022-12-09 · How we verify

NCT05594797

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Recruiting now Phase 2 Last updated 9 December 2022

What this trial tests

Phase 2 trial testing Human BCMA Targeted T Cells Injection in Multiple Myeloma in 100 participants. Currently enrolling.

Timeline

12 July 2022

Primary endpoint
31 July 2025

31 July 2027

Quick facts

Lead sponsor	Hrain Biotechnology Co., Ltd.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	12 July 2022
Primary completion	31 July 2025
Estimated completion	31 July 2027
Sites	2 locations across China

Drugs / interventions tested

Human BCMA Targeted T Cells Injection — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Hrain Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, et al · · 2023 · cited 59× · PMID 37284695 · DOI 10.1080/2162402x.2023.2219591
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
Mishra AK, Gupta A, Dagar G, Das D, et al · · 2023 · cited 29× · PMID 38006053 · DOI 10.3390/vaccines11111721
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T, Van Rhee F, Al Hadidi S. · · 2023 · cited 10× · PMID 37359353 · DOI 10.2147/ott.s370880
A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.
Chen D, Zhu Y, Chen Z, Jiang S, et al · · 2024 · cited 6× · PMID 38869658 · DOI 10.1158/1078-0432.ccr-24-0414

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Hrain Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT06045091 — To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL · EARLY_PHASE1 · recruiting
NCT05651191 — To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL · EARLY_PHASE1 · unknown
NCT05651178 — Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients · EARLY_PHASE1 · recruiting
NCT05223686 — To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. · Phase 1 · unknown
NCT05302648 — To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM · EARLY_PHASE1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05594797 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hrain Biotechnology Co., Ltd.
Last refreshed: 9 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing